Amgen Appoints Beth Seidenberg as Senior Vice President -- Development
THOUSAND OAKS, Calif., Jan 10, 2002 (BUSINESS WIRE) -- Amgen (Nasdaq:AMGN)
announced today that Beth C. Seidenberg, M.D. has been named Senior Vice
President, Development effective January 14, 2002. Dr. Seidenberg will report to
Roger M. Perlmutter, M.D., Ph.D., Executive Vice President -- Research and
Development. She will also serve on the company's executive committee.
Dr. Seidenberg comes to Amgen from the Bristol-Myers Squibb Pharmaceutical
Research Institute (BMS), which she joined in 2000. She served as Senior Vice
President for Global Development. At Bristol she led a 1,500-person organization
with full responsibility for the clinical development of new drug candidates.
"We are extremely pleased that Beth Seidenberg, a globally recognized expert in
immunology and inflammation, has decided to join the Amgen team. Beth has
demonstrated her talent in moving drug candidates with speed and care through
the development process, both at Merck and Bristol-Myers Squibb. She is a real
leader in clinical research," said Dr. Perlmutter.
Prior to joining BMS, she rose quickly during 11 years at the Merck Research
Laboratories to Vice President, with special responsibility in pulmonary
medicine and inflammation. She was also part of the Merck team that evaluated
A graduate of Barnard College and the University of Miami School of Medicine and
thereafter completed her medical residency at Johns Hopkins and the George
Washington University; from 1987 to 1989 Dr. Seidenberg pursued research at
National Institute of Allergy & Infectious Diseases focusing on pulmonary and
immunology research. She is board certified in pediatrics and also in immunology
Dr. Seidenberg's career milestones include the approval and launch of
SINGLAIR(R) for treatment of asthma in adults and children, and the development
and approval of VIOXX(R) for pain management. She is credited with decisive,
effective leadership in bringing both these products to successful approval.
At Amgen she will be responsible for worldwide Clinical Development including
Clinical Operations and Regulatory Affairs.
Amgen is a global biotechnology company that discovers, develops, manufactures
and markets cost-effective human therapeutics based on advances in cellular and
EDITORS NOTE: An electronic version of this news release may be accessed via our
web site at www.Amgen.com. Visit the Corporate Center and click on Amgen News.
Journalists and media representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in the Amgen
News section of the web site.
CONTACT: Amgen, Thousand Oaks
Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)